Company Overview of Profectus Biosciences, Inc.
Profectus Biosciences, Inc., a clinical-stage biotechnology company, designs and develops preventive and therapeutic vaccines. It develops products based on its platform PBS Vax, a prime/boost system of vaccines. The company’s products include GeneVax prime/VesiculoVax boost therapeutic HIV vaccines; and PBS Vax therapeutic vaccines for the treatment of chronic infectious diseases, such as HIV, HPV, HBV, HCV, and HSV-2. Its products also comprise VesiculoVax prophylactic vaccines for public health and biodefense, including Ebola/Marburg, EEVs, Chikungunya, and Lassa; and prophylactic vaccines, such as HIV and Nipah/Hendra vaccines. Profectus Biosciences, Inc. was formerly known as Maryland B...
6411 Beckley Street
Baltimore, MD 21224
Founded in 2002
Key Executives for Profectus Biosciences, Inc.
Executive Director of Operations and Outsourcing
Chief Scientific Officer of Vaccines
Compensation as of Fiscal Year 2015.
Profectus Biosciences, Inc. Key Developments
Profectus BioSciences, Inc. Announces the Results of Study Demonstrating That Single Dose of Vaccine Administered Using the VesiculoVax Vector Platform
Apr 8 15
Profectus BioSciences, Inc. announced the results of a study demonstrating that a single dose of vaccine administered using the company's VesiculoVax vector platform protects non-human primates against challenge with the 'Makona' strain of Ebola virus (previously referred to as the Ebola Guinea strain) that is responsible for the current Ebola outbreak in West Africa. Results of the study are published in the April 9, 2015 issue of the journal, Nature, in an article entitled, 'Single-Dose Attenuated VesiculoVax Vaccines Protect Primates Against Ebola Makona Virus.' The study was authored by researchers at Profectus and the University of Texas Medical Branch (UTMB) at Galveston. In this trial, two candidate VesiculoVax-vectored Ebola vaccines of intermediate and high attenuation were tested, and both were shown to provide complete, single-dose protection of rhesus macaques against illness and death from the Makona strain of Ebola from Guinea, which is responsible for the current outbreak in West Africa. Eight vaccinated and two unvaccinated control macaques were infected with a Makona strain of Ebola virus 28days after receiving a single injection of one of the vaccines. None of the monkeys vaccinated with either vaccine showed any severe signs of illness following infection with the virus, whereas the two unvaccinated animals succumbed to the disease on days seven and eight. Profectus' highly attenuated rVSVN4CT1 VesiculoVax vector used in this study is also the foundation of the Profectus Ebola and Marburg monovalent and trivalent vaccines in development by Profectus with support from the National Institutes of Health (NIH), the U.S. Department of Health and Human Services (HHS) Biomedical Advanced Research and Development Authority (BARDA), and the Department of Defense (DoD) Joint Vaccine Acquisition Program (JVAP). The VesiculoVax platform provides the flexibility to construct vaccine delivery vectors with different levels of attenuation, a capability that enables the identification of vaccines that provide complete protection with level of safety.
Profectus Biosciences, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015
Dec 24 14
Profectus Biosciences, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.
Profectus BioSciences, Inc. Receives $8.6 Million HHS Contract to Accelerate Ebola Vaccine into Human Clinical Studies
Oct 22 14
Profectus BioSciences, Inc. announced that the company has received a contract from the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) aimed at accelerating the advancement of the company's candidate Ebola vaccine into human clinical studies. In previous preclinical studies conducted in collaboration with the National Institutes of Health (NIH) and Department of Defense (DoD) in non-human primates, a single dose of the Profectus vaccine has been shown to provide 100% protection against Ebola Zaire. The one-year contract with the ASPR's Biomedical Advanced Research and Development Authority (BARDA) will provide $5.8 million in funding to conduct toxicology studies to evaluate the safety of the company's novel VesiculoVax(TM) Ebola vaccine candidate and to manufacture the vaccine for use in Phase 1 clinical studies. The contract can be extended to a total of 13 months and $8.6 million. Upon successful completion of these initiatives, Profectus will apply to the U.S. Food and Drug Administration for an Investigational New Drug (IND) designation that would allow initiation of human clinical trials to evaluate the vaccine's safety and immunogenicity in humans. With this most recent funding, Profectus has secured a total of $27.9 million to develop the VesiculoVax(TM) Ebola vaccine, including: HHS, October 2014: $8.6 million; DoD, October 2014: $8.5 million; NIAID, March 2014: $5.4 million; and NIAID, May 2012: $5.4 million.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|